Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma.
Autor: | Diab O; Department of Medicine, Creighton University, Omaha, NE, USA., Mcentire D; Department of Medicine, University of Utah, Salt Lake City, UT, USA., Kassim T; Department of Medicine, Creighton University, Omaha, NE, USA., Nayfeh A; Department of Medicine, Creighton University, Omaha, NE, USA., Dajani AR; Department of Medicine, Norwalk Hospital, Norwalk, CT, USA., Kerfeld M; Department of Pathology, Creighton University, Omaha, NE, USA., Campbell J; Department of Medicine, Creighton University, Omaha, NE, USA., Alsuwaidan A; Department of Anesthesia, Mayo Clinic, Rochester, MN, USA., Hazeem MA; Department of Medicine, Creighton University, Omaha, NE, USA., Gbadamosi-Akindele M; Department of Medicine, Creighton University, Omaha, NE, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Case reports in oncological medicine [Case Rep Oncol Med] 2019 Jan 08; Vol. 2019, pp. 7928752. Date of Electronic Publication: 2019 Jan 08 (Print Publication: 2019). |
DOI: | 10.1155/2019/7928752 |
Abstrakt: | Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |